Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?

Authors

  • Arden R Barry (Pro) Rideau Community Health Services
  • Bradley R Mitchelmore (Con) Chilliwack General Hospital, University of British Columbia

DOI:

https://doi.org/10.4212/cjhp.v71i4.2831

Abstract

-

Downloads

Download data is not yet available.

Downloads

Published

2018-09-05

Issue

Section

Point Counterpoint / Le pour et le contre